
®
Focused pipeline of development candidates where Dualase has a differentiated mechanism of action
Initial focus on treating devastating repeat expansion disorders by precisely collapsing the toxic DNA repeats that drive disease - bringing a potential disease-modifying option to patients who currently have none

In vivo tolerability and efficacy in disease-relevant cell and animal models demonstrating the differentiated advantage of Dualase genome editors
®

Neurodegeneration
Efficient and precise removal of an expanded DNA repeat sequence in a central nervous system (CNS) neurodegenerative disease using dual-guided Dualase encoded in a single adeno-associated virus (AAV) ​
®
Delivery:
Single AAV
Mechanism:
Repeat removal
Differentiated benefits:
-
Precise removal of pathogenic DNA repeats leaving non-pathogenic number
-
Single AAV delivery simplifies manufacturing and dosing and has been used in clinical and commercial products
-
High specificity for target regions and, unlike other genome editors tested, no off-target effects
-
Durable correction of underlying genetic mutation in DNA for potential lasting benefit

Cystic Fibrosis
Mutation-agnostic correction of multiple CF-causing mutations using RNA formulation encapsulated in a proprietary nebulized lipid nanoparticle (LNP) formulation for targeted delivery to the lung
Delivery:
LNP-mRNA
Repair
Mechanism:
Differentiated benefits:
-
Seamless repair without insertions, deletions or bystander base changes
-
'Hotspot' correction of multiple mutations with one Dualase genome editor
-
Direct delivery to lung to address major source of morbidity and mortality
-
Durable correction of underlying genetic mutation compared to RNA- or protein-targeted therapeutics
®

Liver
Correction of base change without any detectable nearby base modifications using RNA formulation encapsulated in a lipid nanoparticle
Delivery:
LNP-mRNA
Mechanism:
Repair
Differentiated benefits:
-
Seamless repair without other detectable bystander base changes
-
Corrects both lung and liver manifestations of the disease with one Dualase genome editor
-
Small RNAs for simpler manufacturing and decreased potential immunogenicity
-
Durable correction of underlying genetic mutation compared to RNA- or protein-targeted therapeutics
